A Call to End Routine Laboratory Monitoring for Patients on Isotretinoin

The study authors argue that clinicians prescribing isotretinoin for acne or other skin conditions should stop ordering routine laboratory monitoring for liver function and lipids. They maintain that evidence shows an exceptionally low risk of these adverse effects. A careful medical history and symptom-based monitoring could reduce patient and provider anxiety and costs.

While streamlined testing is a step in the right direction, a more selective approach is needed, according to Joseph C. Pierson, MD, of the University of Vermont Health. The authors, citing limited evidence, believe that testing can be further limited. They note that while routine monitoring has been a standard practice for decades, modern evidence suggests that testing can be reduced.

Future research should determine if patient outcomes align with the existing information, but if data remain consistent, guidelines for isotretinoin use could be refined.